Immunovaccine Inc








Immunovaccine Inc.


Specialty Stage Position Board
Oncology Vaccine Early PIPE Member
Last update: 08/06/2016


Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax(TM) platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

This impressive collection of assets positions Immunovaccine with an advantageous growth strategy that leverages the unique attributes of DepoVax™ through the development of high-value internal vaccine candidates balanced with the upside of collaborative program advancement.

Contact Immunovaccine Inc.:

1344 Summer Street
Suite 412
Halifax, Nova Scotia, Canada
B3H 0A8

Telephone: (902) 492-1819
Facsimile: (902) 492-0888

For general inquiries, please contact: or (902) 492-1819.

For investor relations & media inquiries, please contact Kimberly Stephens at or (902) 492-1819, ext. 1.

For partnering & business development inquiries, please contact Frederic Ors at (902) 492-1819, ext. 4